The Indian Patent Office has rejected a patent application for an anti-cancer drug for the second time, paving the way for generic versions to potentially enter the market.
Teva has reached a settlement in its patent battle with two pharmaceutical companies, ending all litigation over its ProAir HFA (albuterol sulfate) inhalation aerosol.
Europe’s highest court has said that products used by agrochemical companies to help maintain plants can be given extended patent protection.
Holland & Knight LLP has expanded its IP practice group with the hire of patent litigator Howard Suh as partner.
Stem cell research companies in Canada and Australia have teamed up to support increased research and development in both countries.
Drug giant Merck is to acquire biopharmaceutical company Idenix for $24.50 per share, valuing the purchase at around $3.85 billion.
Irish-based drug manufacturer Actavis has settled its patent dispute with Zydus Pharmaceuticals.
Law firm Dechert LLP has appointed Rüdiger Herrmann as a partner in its Frankfurt office.
AMAG Pharmaceuticals, Inc. has had a US patent covering ferumoxytol extended.
Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.